Tumour necrosis factor in infectious disease

Journal of Pathology

Volumn 230, Issue 2, 2013, Pages 132-147

  Waters, John P ^a   Pober, Jordan S ^b   Bradley, John R ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

immunological response; infection; inflammation; signalling; TNF; TNF receptors

Indexed keywords

ADALIMUMAB; CASPASE 8; ETANERCEPT; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; VASCULAR CELL ADHESION MOLECULE 1;

ACUTE PHASE RESPONSE; BACTERIAL INFECTION; CELL ACTIVATION; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURFACE; CELL SURVIVAL; DEEP VEIN THROMBOSIS; DENDRITIC CELL; DISSEMINATED INTRAVASCULAR CLOTTING; ENZYME ACTIVITY; EPITHELIUM CELL; EPSTEIN BARR VIRUS; FEVER; GENETIC VARIABILITY; HEMATOPOIESIS; HEPATITIS C; HUMAN; HUMAN ADENOVIRUS; HUMAN CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 8; INFLAMMATION; INNATE IMMUNITY; INTERNALIZATION; LISTERIA MONOCYTOGENES; MACROPHAGE; MALARIA; MOUSE; NONHUMAN; PARASITOSIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; TISSUE INJURY; TUBERCULOSIS; VASCULAR ENDOTHELIUM; VIRUS INFECTION;

ANIMALS; CELL DEATH; COMMUNICABLE DISEASES; GENE EXPRESSION REGULATION; HUMANS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84877749131     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4187     Document Type: Review

References (171)

1. Adrain C, Zettl M, Christova Y, et al,. Tumor necrosis factor signaling requires iRhom2 to promote trafficking and activation of TACE. Science 2012; 335: 225-228.
2. Bradley JR, Thiru S, Pober JS,. Disparate localization of 55-kd and 75-kd tumor necrosis factor receptors in human endothelial cells. Am J Pathol 1995; 146: 27-32.
3. Wang J, Al-Lamki RS, Zhang H, et al,. Histamine antagonizes tumor necrosis factor (TNF) signaling by stimulating TNF receptor shedding from the cell surface and Golgi storage pool. J Biol Chem 2003; 278: 21751-21760.
4. Pinckard JK, Sheehan KC, Schreiber RD,. Ligand-induced formation of p55 and p75 tumor necrosis factor receptor heterocomplexes on intact cells. J Biol Chem 1997; 272: 10784-10789.
5. Tartaglia LA, Pennica D, Goeddel DV,. Ligand passing: the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor. J Biol Chem 1993; 268: 18542-18548.
6. Chan FK, Chun HJ, Zheng L, et al,. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 2000; 288: 2351-2354.
7. Endres R, Häcker G, Brosch I, et al,. Apparently normal tumor necrosis factor receptor 1 signaling in the absence of the silencer of death domains. Mol Cell Biol 2003; 23: 6609-6617.
8. Hsu H, Huang J, Shu HB, et al,. TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity 1996; 4: 387-396.
9. Takeuchi M, Rothe M, Goeddel DV,. Anatomy of TRAF2. Distinct domains for nuclear factor-κB activation and association with tumor necrosis factor signaling proteins. J Biol Chem 1996; 271: 19935-19942.
10. Tsao DH, McDonagh T, Telliez JB, et al,. Solution structure of N-TRADD and characterization of the interaction of N-TRADD and C-TRAF2, a key step in the TNFR1 signaling pathway. Mol Cell 2000; 5: 1051-1057.
11. Jones SJ, Ledgerwood EC, Prins JB, et al,. TNF recruits TRADD to the plasma membrane but not the trans-Golgi network, the principal subcellular location of TNF-R1. J Immunol 1999; 162: 1042-1048.
12. Bradley JR, Johnson DR, Pober JS,. Four different classes of inhibitors of receptor-mediated endocytosis decrease tumor necrosis factor-induced gene expression in human endothelial cells. J Immunol 1993; 150: 5544-5555.
13. Schütze S, Machleidt T, Adam D, et al,. Inhibition of receptor internalization by monodansylcadaverine selectively blocks p55 tumor necrosis factor receptor death domain signaling. J Biol Chem 1999; 274: 10203-10212.
14. Yang J, Lin Y, Guo Z, et al,. The essential role of MEKK3 in TNF-induced NF-κB activation. Nat Immunol 2001; 2: 620-624.
15. Blonska M, Shambharkar PB, Kobayashi M, et al,. TAK1 is recruited to the tumor necrosis factor-α (TNF-α) receptor 1 complex in a receptor-interacting protein (RIP)-dependent manner and cooperates with MEKK3 leading to NF-κB activation. J Biol Chem 2005; 280: 43056-43063.
16. Baldwin AS,. The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol 1996; 14: 649-683.
17. Devin A, Lin Y, Yamaoka S, et al,. The α- and β-subunits of IκB kinase (IKK) mediate TRAF2-dependent IKK recruitment to tumor necrosis factor (TNF) receptor 1 in response to TNF. Mol Cell Biol 2001; 21: 3986-3994.
18. Wen AY, Sakamoto KM, Miller LS,. The role of the transcription factor CREB in immune function. J Immunol 2010; 185: 6413-6419.
19. Nishitoh H, Saitoh M, Mochida Y, et al,. ASK1 is essential for JNK/SAPK activation by TRAF2. Mol Cell 1998; 2: 389-395.
20. Song HY, Rothe M, Goeddel DV,. The tumor necrosis factor-inducible zinc finger protein A20 interacts with TRAF1/TRAF2 and inhibits NF-κB activation. Proc Natl Acad Sci USA 1996; 93: 6721-6725.
21. Hsu H, Shu HB, Pan MG, et al,. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 1996; 84: 299-308.
22. Wertz IE, O'Rourke KM, Zhou H, et al,. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling. Nature 2004; 430: 694-699.
23. Bonnet MC, Preukschat D, Welz PS, et al,. The adaptor protein FADD protects epidermal keratinocytes from necroptosis in vivo and prevents skin inflammation. Immunity 2011; 35: 572-582.
24. Welz PS, Wullaert A, Vlantis K, et al,. FADD prevents RIP3-mediated epithelial cell necrosis and chronic intestinal inflammation. Nature 2011; 477: 330-334.
25. Sun X, Yin J, Starovasnik MA, et al,. Identification of a novel homotypic interaction motif required for the phosphorylation of receptor-interacting protein (RIP) by RIP3. J Biol Chem 2002; 277: 9505-9511.
26. Oberst A, Dillon CP, Weinlich R, et al,. Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent necrosis. Nature 2011; 471: 363-367.
27. Schwabe RF, Uchinami H, Qian T, et al,. Differential requirement for c-Jun NH2-terminal kinase in TNFα- and Fas-mediated apoptosis in hepatocytes. FASEB J 2004; 18: 720-722.
28. Gabai VL, Mabuchi K, Mosser DD, et al,. Hsp72 and stress kinase c-jun N-terminal kinase regulate the bid-dependent pathway in tumor necrosis factor-induced apoptosis. Mol Cell Biol 2002; 22: 3415-3424.
29. Wadgaonkar R, Pierce JW, Somnay K, et al,. Regulation of c-Jun N-terminal kinase and p38 kinase pathways in endothelial cells. Am J Respir Cell Mol Biol 2004; 31: 423-431.
30. Duriez PJ, Wong F, Dorovini-Zis K, et al,. A1 functions at the mitochondria to delay endothelial apoptosis in response to tumor necrosis factor. J Biol Chem 2000; 275: 18099-18107.
31. Xu XS, Vanderziel C, Bennett CF, et al,. A role for c-Raf kinase and Ha-Ras in cytokine-mediated induction of cell adhesion molecules. J Biol Chem 1998; 273: 33230-33238.
32. Jacinto E, Facchinetti V, Liu D, et al,. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 2006; 127: 125-137.
33. Adam-Klages S, Adam D, Wiegmann K, et al,. FAN, a novel WD-repeat protein, couples the p55 TNF-receptor to neutral sphingomyelinase. Cell 1996; 86: 937-947.
34. Vandanmagsar B, Youm YH, Ravussin A, et al,. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med 2011; 17: 179-188.
35. Rothe M, Wong SC, Henzel WJ, et al,. A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. Cell 1994; 78: 681-692.
36. Rothe M, Sarma V, Dixit VM, et al,. TRAF2-mediated activation of NF-κB by TNF receptor 2 and CD40. Science 1995; 269: 1424-1427.
37. Grech AP, Gardam S, Chan T, et al,. Tumor necrosis factor receptor 2 (TNFR2) signaling is negatively regulated by a novel, carboxyl-terminal TNFR-associated factor 2 (TRAF2)-binding site. J Biol Chem 2005; 280: 31572-31581.
38. Zhao Y, Conze DB, Hanover JA, et al,. Tumor necrosis factor receptor 2 signaling induces selective c-IAP1-dependent ASK1 ubiquitination and terminates mitogen-activated protein kinase signaling. J Biol Chem 2007; 282: 7777-7782.
39. Pan S, An P, Zhang R, et al,. Etk/Bmx as a tumor necrosis factor receptor type 2-specific kinase: role in endothelial cell migration and angiogenesis. Mol Cell Biol 2002; 22: 7512-7523.
40. Zhang R, Xu Y, Ekman N, et al,. Etk/Bmx transactivates vascular endothelial growth factor 2 and recruits phosphatidylinositol 3-kinase to mediate the tumor necrosis factor-induced angiogenic pathway. J Biol Chem 2003; 278: 51267-51276.
41. Al-Lamki RS, Sadler TJ, Wang J, et al,. Tumor necrosis factor receptor expression and signaling in renal cell carcinoma. Am J Pathol 2010; 177: 943-954.
42. Qiu Y, Robinson D, Pretlow TG, et al,. Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3′-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells. Proc Natl Acad Sci USA 1998; 95: 3644-3649.
43. Ban L, Zhang J, Wang L, et al,. Selective death of autoreactive T cells in human diabetes by TNF or TNF receptor 2 agonism. Proc Natl Acad Sci USA 2008; 105: 13644-13649.
44. Kim EY, Teh SJ, Yang J, et al,. TNFR2-deficient memory CD8 T cells provide superior protection against tumor cell growth. J Immunol 2009; 183: 6051-6057.
45. + T cells. Eur J Immunol 2011; 41: 335-344.
46. Mark KS, Trickler WJ, Miller DW,. Tumor necrosis factor-α induces cyclooxygenase-2 expression and prostaglandin release in brain microvessel endothelial cells. J Pharmacol Exp Ther 2001; 297: 1051-1058.
47. Clark PR, Manes TD, Pober JS, et al,. Increased ICAM-1 expression causes endothelial cell leakiness, cytoskeletal reorganization and junctional alterations. J Invest Dermatol 2007; 127: 762-774.
48. Tichelaar YI, Kluin-Nelemans HJ, Meijer K,. Infections and inflammatory diseases as risk factors for venous thrombosis. A systematic review. Thromb Haemost 2012; 107: 827-837.
49. Levi M, van der Poll T, Schultz M,. Systemic versus localized coagulation activation contributing to organ failure in critically ill patients. Semin Immunopathol 2012; 34: 167-179.
50. Engelmann B, Massberg S,. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol 2013; 13: 34-45.
51. Nan B, Lin P, Lumsden AB, et al,. Effects of TNF-α and curcumin on the expression of thrombomodulin and endothelial protein C receptor in human endothelial cells. Thromb Res 2005; 115: 417-426.
52. Bevilacqua MP, Pober JS, Majeau GR, et al,. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci USA 1986; 83: 4533-4537.
53. Nawroth PP, Stern DM,. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986; 163: 740-745.
54. Biemond BJ, Levi M, Ten Cate H, et al,. Plasminogen activator and plasminogen activator inhibitor I release during experimental endotoxaemia in chimpanzees: effect of interventions in the cytokine and coagulation cascades. Clin Sci (Lond) 1995; 88: 587-594.
55. Sawdey MS, Loskutoff DJ,. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-α, and transforming growth factor-β. J Clin Invest 1991; 88: 1346-1353.
56. van der Poll T, Coyle SM, Levi M, et al,. Effect of a recombinant dimeric tumor necrosis factor receptor on inflammatory responses to intravenous endotoxin in normal humans. Blood 1997; 89: 3727-3734.
57. van der Poll T, Büller HR, ten Cate H, et al,. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990; 322: 1622-1627.
58. Bombeli T, Karsan A, Tait JF, et al,. Apoptotic vascular endothelial cells become procoagulant. Blood 1997; 89: 2429-2442.
59. Greeno EW, Bach RR, Moldow CF,. Apoptosis is associated with increased cell surface tissue factor procoagulant activity. Lab Invest 1996; 75: 281-289.
60. Mallat Z, Benamer H, Hugel B, et al,. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 2000; 101: 841-843.
61. Harder J, Meyer-Hoffert U, Teran LM, et al,. Mucoid Pseudomonas aeruginosa, TNF-α, and IL-1β, but not IL-6, induce human β-defensin-2 in respiratory epithelia. Am J Respir Cell Mol Biol 2000; 22: 714-721.
62. Harder J, Bartels J, Christophers E, et al,. Isolation and characterization of human β-defensin-3, a novel human inducible peptide antibiotic. J Biol Chem 2001; 276: 5707-5713.
63. Albanesi C, Fairchild HR, Madonna S, et al,. IL-4 and IL-13 negatively regulate TNF-α- and IFN-γ-induced β-defensin expression through STAT-6, suppressor of cytokine signaling (SOCS)-1, and SOCS-3. J Immunol 2007; 179: 984-992.
64. Kota S, Sabbah A, Chang TH, et al,. Role of human β-defensin-2 during tumor necrosis factor-α/NF-κB-mediated innate antiviral response against human respiratory syncytial virus. J Biol Chem 2008; 283: 22417-22429.
65. + cells. J Immunol 2001; 167: 3329-3338.
66. Wesemann DR, Benveniste EN,. STAT-1α and IFNγ as modulators of TNFα signaling in macrophages: regulation and functional implications of the TNF receptor 1:STAT-1α complex. J Immunol 2003; 171: 5313-5319.
67. Dieu MC, Vanbervliet B, Vicari A, et al,. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med 1998; 188: 373-386.
68. Miwa S, Nishida H, Tanzawa Y, et al,. TNF-α and tumor lysate promote the maturation of dendritic cells for immunotherapy for advanced malignant bone and soft tissue tumors. PLoS One 2012; 7: e52926.
69. Le Roux D, Le Bon A, Dumas A, et al,. Antigen stored in dendritic cells after macropinocytosis is released unprocessed from late endosomes to target B cells. Blood 2012; 119: 95-105.
70. Fernandez NC, Lozier A, Flament C, et al,. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 1999; 5: 405-411.
71. de Saint-Vis B, Fugier-Vivier I, Massacrier C, et al,. The cytokine profile expressed by human dendritic cells is dependent on cell subtype and mode of activation. J Immunol 1998; 160: 1666-1676.
72. Fei M, Bhatia S, Oriss TB, et al,. TNF-α from inflammatory dendritic cells (DCs) regulates lung IL-17A/IL-5 levels and neutrophilia versus eosinophilia during persistent fungal infection. Proc Natl Acad Sci USA 2011; 108: 5360-5365.
73. Dinarello CA, Cannon JG, Wolff SM, et al,. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med 1986; 163: 1433-1450.
74. Inoue W, Somay G, Poole S, et al,. Immune-to-brain signaling and central prostaglandin E2 synthesis in fasted rats with altered lipopolysaccharide- induced fever. Am J Physiol Regul Integr Comp Physiol 2008; 295: R133-143.
75. Conti B, Tabarean I, Andrei C, et al,. Cytokines and fever. Front Biosci 2004; 9: 1433-1449.
76. Konsman JP, Parnet P, Dantzer R,. Cytokine-induced sickness behaviour: mechanisms and implications. Trends Neurosci 2002; 25: 154-159.
77. Salman H, Bergman M, Bessler H, et al,. Ultrastructure and phagocytic activity of rat peritoneal macrophages exposed to low temperatures in vitro. Cryobiology 2000; 41: 66-71.
78. + T cells into effector cells is enhanced by physiological range hyperthermia. J Leukoc Biol 2011; 90: 951-962.
79. Rojas S, Richards K, Jancovich JK, et al,. Influence of temperature on Ranavirus infection in larval salamanders Ambystoma tigrinum. Dis Aquat Organ 2005; 63: 95-100.
80. Trammell RA, Toth LA,. Markers for predicting death as an outcome for mice used in infectious disease research. Comp Med 2011; 61: 492-498.
81. Ramadori G, Van Damme J, Rieder H, et al,. Interleukin 6, the third mediator of acute-phase reaction, modulates hepatic protein synthesis in human and mouse. Comparison with interleukin 1β and tumor necrosis factor-α. Eur J Immunol 1988; 18: 1259-1264.
82. Caux C, Favre C, Saeland S, et al,. Potentiation of early hematopoiesis by tumor necrosis factor-α is followed by inhibition of granulopoietic differentiation and proliferation. Blood 1991; 78: 635-644.
83. Backx B, Broeders L, Bot FJ, et al,. Positive and negative effects of tumor necrosis factor on colony growth from highly purified normal marrow progenitors. Leukemia 1991; 5: 66-70.
84. Rusten LS, Smeland EB, Jacobsen FW, et al,. Tumor necrosis factor-α inhibits stem cell factor-induced proliferation of human bone marrow progenitor cells in vitro. Role of p55 and p75 tumor necrosis factor receptors. J Clin Invest 1994; 94: 165-172.
85. Baxter GT, Kuo RC, Jupp OJ, et al,. Tumor necrosis factor-α mediates both apoptotic cell death and cell proliferation in a human hematopoietic cell line dependent on mitotic activity and receptor subtype expression. J Biol Chem 1999; 274: 9539-9547.
86. Mizrahi K, Stein J, Yaniv I, et al,. TNF-α has tropic rather than apoptotic activity in human hematopoietic progenitors: involvement of TNF receptor-1 and caspase-8. Stem Cells 2013; 31: 156-166.
87. Tracey KJ, Beutler B, Lowry SF, et al,. Shock and tissue injury induced by recombinant human cachectin. Science 1986; 234: 470-474.
88. Beutler B, Milsark IW, Cerami AC,. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985; 229: 869-871.
89. Tracey KJ, Fong Y, Hesse DG, et al,. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330: 662-664.
90. Eskandari MK, Bolgos G, Miller C, et al,. Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. J Immunol 1992; 148: 2724-2730.
91. Echtenacher B, Weigl K, Lehn N, et al,. Tumor necrosis factor-dependent adhesions as a major protective mechanism early in septic peritonitis in mice. Infect Immun 2001; 69: 3550-3555.
92. Fisher CJ, Agosti JM, Opal SM, et al,. Treatment of septic shock with the tumor necrosis factor receptor-Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996; 334: 1697-1702.
93. Cohen J, Carlet J,. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-α in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med 1996; 24: 1431-1440.
94. Abraham E, Glauser MP, Butler T, et al,. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group. J Am Med Assoc 1997; 277: 1531-1538.
95. Abraham E, Anzueto A, Gutierrez G, et al,. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet 1998; 351: 929-933.
96. Abraham E, Laterre PF, Garbino J, et al,. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1342 patients. Crit Care Med 2001; 29: 503-510.
97. Panacek EA, Marshall JC, Albertson TE, et al,. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab′)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med 2004; 32: 2173-2182.
98. Rice TW, Wheeler AP, Morris PE, et al,. Safety and efficacy of affinity-purified, anti-tumor necrosis factor-α, ovine fab for injection (CytoFab) in severe sepsis. Crit Care Med 2006; 34: 2271-2281.
99. Qiu P, Cui X, Barochia A, et al,. The evolving experience with therapeutic TNF inhibition in sepsis: considering the potential influence of risk of death. Expert Opin Investig Drugs 2011; 20: 1555-1564.
100. Cooper AM, Khader SA,. The role of cytokines in the initiation, expansion, and control of cellular immunity to tuberculosis. Immunol Rev 2008; 226: 191-204.
101. Beham AW, Puellmann K, Laird R, et al,. A TNF-regulated recombinatorial macrophage immune receptor implicated in granuloma formation in tuberculosis. PLoS Pathog 2011; 7: e1002375.
102. Cavalcanti YV, Brelaz MC, Neves JK, et al,. Role of TNF-α, IFN-γ and IL-10 in the development of pulmonary tuberculosis. Pulm Med 2012; 2012: 745483.
103. Allie N, Alexopoulou L, Quesniaux VJ, et al,. Protective role of membrane tumour necrosis factor in the host's resistance to mycobacterial infection. Immunology 2008; 125: 522-534.
104. Olleros ML, Vesin D, Bisig R, et al,. Membrane-bound TNF induces protective immune responses to M. bovis BCG infection: regulation of memTNF and TNF receptors comparing two memTNF molecules. PLoS One 2012; 7: e31469.
105. Kähler AK, Persson AS, Sánchez F, et al,. A new coding mutation in the TNF-α leader sequence in tuberculosis-sensitive I/St mice causes higher secretion levels of soluble TNF-α. Genes Immun 2005; 6: 620-627.
106. Tobin DM, Roca FJ, Oh SF, et al,. Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell 2012; 148: 434-446.
107. Nakane A, Minagawa T, Kato K,. Endogenous tumor necrosis factor (cachectin) is essential to host resistance against Listeria monocytogenes infection. Infect Immun 1988; 56: 2563-2569.
108. Samsom JN, Langermans JA, Savelkoul HF, et al,. Tumour necrosis factor, but not interferon-γ, is essential for acquired resistance to Listeria monocytogenes during a secondary infection in mice. Immunology 1995; 86: 256-262.
109. Virna S, Deckert M, Lütjen S, et al,. TNF is important for pathogen control and limits brain damage in murine cerebral listeriosis. J Immunol 2006; 177: 3972-3982.
110. Musicki K, Briscoe H, Tran S, et al,. Differential requirements for soluble and transmembrane tumor necrosis factor in the immunological control of primary and secondary Listeria monocytogenes infection. Infect Immun 2006; 74: 3180-3189.
111. McIlwain DR, Lang PA, Maretzky T, et al,. iRhom2 regulation of TACE controls TNF-mediated protection against Listeria and responses to LPS. Science 2012; 335: 229-232.
112. Zhou H, Monack DM, Kayagaki N, et al,. Yersinia virulence factor YopJ acts as a deubiquitinase to inhibit NF-κB activation. J Exp Med 2005; 202: 1327-1332.
113. Ruckdeschel K, Harb S, Roggenkamp A, et al,. Yersinia enterocolitica impairs activation of transcription factor NF-κB: involvement in the induction of programmed cell death and in the suppression of the macrophage tumor necrosis factor-α production. J Exp Med 1998; 187: 1069-1079.
114. Schesser K, Spiik AK, Dukuzumuremyi JM, et al,. The yopJ locus is required for Yersinia-mediated inhibition of NF-κB activation and cytokine expression: YopJ contains a eukaryotic SH2-like domain that is essential for its repressive activity. Mol Microbiol 1998; 28: 1067-1079.
115. Caron E, Gross A, Liautard JP, et al,. Brucella species release a specific, protease-sensitive, inhibitor of TNF-α expression, active on human macrophage-like cells. J Immunol 1996; 156: 2885-2893.
116. Leal-Berumen I, Snider DP, Barajas-Lopez C, et al,. Cholera toxin increases IL-6 synthesis and decreases TNF-α production by rat peritoneal mast cells. J Immunol 1996; 156: 316-321.
117. Hoover DL, Friedlander AM, Rogers LC, et al,. Anthrax edema toxin differentially regulates lipopolysaccharide-induced monocyte production of tumor necrosis factor-α and interleukin-6 by increasing intracellular cyclic AMP. Infect Immun 1994; 62: 4432-4439.
118. Wilson M, Reddi K, Henderson B,. Cytokine-inducing components of periodontopathogenic bacteria. J Periodontal Res 1996; 31: 393-407.
119. Tateda K, Ishii Y, Horikawa M, et al,. The Pseudomonas aeruginosa autoinducer N-3-oxododecanoyl homoserine lactone accelerates apoptosis in macrophages and neutrophils. Infect Immun 2003; 71: 5785-5793.
120. Redpath S, Ghazal P, Gascoigne NR,. Hijacking and exploitation of IL-10 by intracellular pathogens. Trends Microbiol 2001; 9: 86-92.
121. Mack C, Sickmann A, Lembo D, et al,. Inhibition of proinflammatory and innate immune signaling pathways by a cytomegalovirus RIP1-interacting protein. Proc Natl Acad Sci USA 2008; 105: 3094-3099.
122. Upton JW, Kaiser WJ, Mocarski ES,. Cytomegalovirus M45 cell death suppression requires receptor-interacting protein (RIP) homotypic interaction motif (RHIM)-dependent interaction with RIP1. J Biol Chem 2008; 283: 16966-16970.
123. Upton JW, Kaiser WJ, Mocarski ES,. DAI/ZBP1/DLM-1 complexes with RIP3 to mediate virus-induced programmed necrosis that is targeted by murine cytomegalovirus vIRA. Cell Host Microbe 2012; 11: 290-297.
124. Ray CA, Black RA, Kronheim SR, et al,. Viral inhibition of inflammation: cowpox virus encodes an inhibitor of the interleukin-1β converting enzyme. Cell 1992; 69: 597-604.
125. Enari M, Hug H, Nagata S,. Involvement of an ICE-like protease in Fas-mediated apoptosis. Nature 1995; 375: 78-81.
126. Wagenknecht B, Schulz JB, Gulbins E, et al,. Crm-A, bcl-2 and NDGA inhibit CD95L-induced apoptosis of malignant glioma cells at the level of caspase 8 processing. Cell Death Differ 1998; 5: 894-900.
127. Reeves MB, Sinclair JH,. Analysis of latent viral gene expression in natural and experimental latency models of human cytomegalovirus and its correlation with histone modifications at a latent promoter. J Gen Virol 2010; 91: 599-604.
128. Benedict CA, Butrovich KD, Lurain NS, et al,. Cutting edge: a novel viral TNF receptor superfamily member in virulent strains of human cytomegalovirus. J Immunol 1999; 162: 6967-6970.
129. Poole E, Groves I, MacDonald A, et al,. Identification of TRIM23 as a cofactor involved in the regulation of NF-κB by human cytomegalovirus. J Virol 2009; 83: 3581-3590.
130. Le VT, Trilling M, Hengel H,. The cytomegaloviral protein pUL138 acts as potentiator of tumor necrosis factor (TNF) receptor 1 surface density to enhance ULb′-encoded modulation of TNF-α signaling. J Virol 2011; 85: 13260-13270.
131. Baillie J, Sahlender DA, Sinclair JH,. Human cytomegalovirus infection inhibits tumor necrosis factor-α (TNF-α) signaling by targeting the 55-kDa TNF-α receptor. J Virol 2003; 77: 7007-7016.
132. Taylor RT, Bresnahan WA,. Human cytomegalovirus IE86 attenuates virus- and tumor necrosis factor-α-induced NF-κB-dependent gene expression. J Virol 2006; 80: 10763-10771.
133. Sundararajan R, Cuconati A, Nelson D, et al,. Tumor necrosis factor-α induces Bax-Bak interaction and apoptosis, which is inhibited by adenovirus E1B 19 K. J Biol Chem 2001; 276: 45120-45127.
134. Chin YR, Horwitz MS,. Mechanism for removal of tumor necrosis factor receptor 1 from the cell surface by the adenovirus RIDα/β complex. J Virol 2005; 79: 13606-13617.
135. Schneider-Brachert W, Tchikov V, Merkel O, et al,. Inhibition of TNF receptor 1 internalization by adenovirus 14.7 K as a novel immune escape mechanism. J Clin Invest 2006; 116: 2901-2913.
136. Kieser A, Kaiser C, Hammerschmidt W,. LMP1 signal transduction differs substantially from TNF receptor 1 signaling in the molecular functions of TRADD and TRAF2. EMBO J 1999; 18: 2511-2521.
137. Schneider F, Neugebauer J, Griese J, et al,. The viral oncoprotein LMP1 exploits TRADD for signaling by masking its apoptotic activity. PLoS Biol 2008; 6: e8.
138. Mesri EA, Cesarman E, Boshoff C,. Kaposi's sarcoma and its associated herpesvirus. Nat Rev Cancer 2010; 10: 707-719.
139. Field N, Low W, Daniels M, et al,. KSHV vFLIP binds to IKK-γ to activate IKK. J Cell Sci 2003; 116: 3721-3728.
140. Zhu N, Khoshnan A, Schneider R, et al,. Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis. J Virol 1998; 72: 3691-3697.
141. Joo M, Hahn YS, Kwon M, et al,. Hepatitis C virus core protein suppresses NF-κB activation and cyclooxygenase-2 expression by direct interaction with IκB kinase-β. J Virol 2005; 79: 7648-7657.
142. Wilhelm P, Wiede F, Meissner A, et al,. TNF but not Fas ligand provides protective anti-L. major immunity in C57BL/6 mice. Microbes Infect 2005; 7: 1461-1468.
143. Pérez AR, Berbert LR, Lepletier A, et al,. TNF-α is involved in the abnormal thymocyte migration during experimental Trypanosoma cruzi infection and favors the export of immature cells. PLoS One 2012; 7: e34360.
144. Delair E, Creuzet C, Dupouy-Camet J, et al,. In vitro effect of TNF-α and IFN-γ in retinal cell infection with Toxoplasma gondii. Invest Ophthalmol Vis Sci 2009; 50: 1754-1760.
145. Cowman AF, Berry D, Baum J,. The cellular and molecular basis for malaria parasite invasion of the human red blood cell. J Cell Biol 2012; 198: 961-971.
146. Depinay N, Franetich JF, Grüner AC, et al,. Inhibitory effect of TNF-α on malaria pre-erythrocytic stage development: influence of host hepatocyte/parasite combinations. PLoS One 2011; 6: e17464.
147. Kwiatkowski D, Hill AV, Sambou I, et al,. TNF concentration in fatal cerebral, non-fatal cerebral, and uncomplicated Plasmodium falciparum malaria. Lancet 1990; 336: 1201-1204.
148. Mordmüller BG, Metzger WG, Juillard P, et al,. Tumor necrosis factor in Plasmodium falciparum malaria: high plasma level is associated with fever, but high production capacity is associated with rapid fever clearance. Eur Cytokine Netw 1997; 8: 29-35.
149. Rudin W, Eugster HP, Bordmann G, et al,. Resistance to cerebral malaria in tumor necrosis factor-α/β-deficient mice is associated with a reduction of intercellular adhesion molecule-1 up-regulation and T helper type 1 response. Am J Pathol 1997; 150: 257-266.
150. Kwiatkowski D, Molyneux ME, Stephens S, et al,. Anti-TNF therapy inhibits fever in cerebral malaria. Q J Med 1993; 86: 91-98.
151. van Hensbroek MB, Palmer A, Onyiorah E, et al,. The effect of a monoclonal antibody to tumor necrosis factor on survival from childhood cerebral malaria. J Infect Dis 1996; 174: 1091-1097.
152. Knight JC, Udalova I, Hill AV, et al,. A polymorphism that affects OCT-1 binding to the TNF promoter region is associated with severe malaria. Nat Genet 1999; 22: 145-150.
153. McGuire W, Hill AV, Allsopp CE, et al,. Variation in the TNF-α promoter region associated with susceptibility to cerebral malaria. Nature 1994; 371: 508-510.
154. Stoelcker B, Hehlgans T, Weigl K, et al,. Requirement for tumor necrosis factor receptor 2 expression on vascular cells to induce experimental cerebral malaria. Infect Immun 2002; 70: 5857-5859.
155. Pfeffer K, Matsuyama T, Kündig TM, et al,. Mice deficient for the 55 kDa tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 1993; 73: 457-467.
156. Rothe J, Lesslauer W, Lötscher H, et al,. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 1993; 364: 798-802.
157. Peschon JJ, Torrance DS, Stocking KL, et al,. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J Immunol 1998; 160: 943-952.
158. Roach DR, Bean AG, Demangel C, et al,. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 2002; 168: 4620-4627.
159. Oliveira CF, Manzoni-de-Almeida D, Mello PS, et al,. Characterization of chronic cutaneous lesions from TNF-receptor-1-deficient mice infected by Leishmania major. Clin Dev Immunol 2012; 2012: 865708.
160. Fujita M, Ikegame S, Harada E, et al,. TNF receptor 1 and 2 contribute in different ways to resistance to Legionella pneumophila-induced mortality in mice. Cytokine 2008; 44: 298-303.
161. Calzascia T, Pellegrini M, Hall H, et al,. TNF-α is critical for antitumor but not antiviral T cell immunity in mice. J Clin Invest 2007; 117: 3833-3845.
162. Tian T, Dubin K, Jin Q, et al,. Disruption of TNF-α/TNFR1 function in resident skin cells impairs host immune response against cutaneous vaccinia virus infection. J Invest Dermatol 2012; 132: 1425-1434.
163. Vilela MC, Lima GK, Rodrigues DH, et al,. TNFR1 plays a critical role in the control of severe HSV-1 encephalitis. Neurosci Lett 2010; 479: 58-62.
164. Waters JP, Pober JS, Bradley JR,. Tumor necrosis factor and cancer. J Pathol 2013; in press.
165. Listing J, Strangfeld A, Kary S, et al,. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005; 52: 3403-3412.
166. Galloway JB, Hyrich KL, Mercer LK, et al,. Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011; 70: 1810-1814.
167. Dixon WG, Watson K, Lunt M, et al,. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006; 54: 2368-2376.
168. Askling J, Fored CM, Brandt L, et al,. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 2007; 66: 1339-1344.
169. Atzeni F, Sarzi-Puttini P, Botsios C, et al,. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmun Rev 2012; 12: 225-229.
170. Kim SY, Solomon DH,. Tumor necrosis factor blockade and the risk of viral infection. Nat Rev Rheumatol 2010; 6: 165-174.
171. Strangfeld A, Listing J, Herzer P, et al,. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-α agents. J Am Med Assoc 2009; 301: 737-744.